The FDA sent out an update on March 4 regarding drugs that are currently in shortage:
- Atropine Sulfate Injection (Updated – Currently in Shortage)
- Calcium Chloride Injection, USP (Updated – Currently in Shortage)
- Enoxaparin Sodium Injection (New – Discontinuation)
- Epinephrine Injection (Updated – Currently in Shortage)
- Fentanyl Citrate (Sublimaze) Injection (Updated – Currently in Shortage)
- Imipenem and Cilastatin for Injection, USP (Updated – Currently in Shortage)
- Lidocaine Hydrochloride (Xylocaine) Injection (Updated – Currently in Shortage)
- Morphine Sulfate Injection, USP, CII, (Preservative-Free)(For PCA Use Only) (Updated – Currently in Shortage)
- Multi-Vitamin Infusion (Adult and Pediatric) (Updated – Currently in Shortage)
- Piperacillin and Tazobactam (Zosyn) Injection (Updated – Currently in Shortage)
- Potassium Chloride Injection (Updated – Currently in Shortage)
- Sodium Bicarbonate Injection, USP (Updated – Currently in Shortage)
- Sodium Chloride 0.9% Injection Bags (Updated – Currently in Shortage)
- Sodium Chloride 23.4% Injection (Currently in Shortage)
- Tobramycin Injection (Updated – Currently in Shortage)
According to the FDA:
“A drug receives Resolved status when the Drug Shortages Staff (DSS) determines that the market is covered, based on information from all manufacturers. The market is considered covered when supply is available from at least one manufacturer to cover total market demand. However, some manufacturers may not have all presentations available. DSS monitors the supply of products with Resolved status. For the most current supply information, contact the manufacturers.”
Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!
